FIELD: pharmaceutical industry; medicine.
SUBSTANCE: group of inventions relates to the pharmaceutical industry and medicine. Disclosed is a combination method for the treatment of COVID-19 (SARS-CoV-2). According to the method, two drugs in therapeutically effective amounts and ratios are injected sequentially or simultaneously into the body of a patient with COVID-19. One of these drugs includes aprotinin and the other one includes favipiravir, which is a SARS-CoV-2 replication inhibitor. Also disclosed is a combination anti-coronavirus drug for use in the specified method.
EFFECT: group of inventions provides a synergistic effect in treatment of COVID-19 (SARS-CoV-2) and can significantly shorten the treatment time and reduce the risk of unwanted side effects.
2 cl, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CORONAVIRUS AGENT FOR COVID-19 COMBINATION THERAPY (SARS-COV-2) | 2020 |
|
RU2742116C1 |
| PHARMACEUTICAL KIT FOR COMBINATION THERAPY OF COVID-19 (SARS-COV-2) AND METHOD OF ITS APPLICATION | 2020 |
|
RU2746161C1 |
| ANTI-SARS-CoV-2-VIRAL PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 2020 |
|
RU2764444C1 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| ANTI-COVID-19 (SARS-COV-2) VIRAL PHARMACEUTICAL COMPOSITION | 2020 |
|
RU2731932C1 |
| ANTICORONAVIRUS THERAPEUTIC AGENT - SUBSTITUTED 7-HYDROXY-3,4,12,12A-TETRAHYDRO-1H-[1,4]OXAZINO[3,4-C]PYRIDO[2,1-F][1,2,4]TRIAZINE-6,8-DIONE FOR THE PREVENTION AND TREATMENT OF COVID-19 | 2020 |
|
RU2745985C1 |
| ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
| METHOD FOR TREATING PATIENTS WITH HIV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES WITH MODERATE AND SEVERE COVID-19 | 2022 |
|
RU2793414C1 |
| METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
| APPLICATION OF A DERIVATIVE OF 1,3,5-TRIAZINE-2,4-DIAMINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2 | 2021 |
|
RU2780249C1 |
